Sandra Ann Springer MD
Associate Professor of Medicine (AIDS) and Associate Clinical Professor of Nursing; Director, Infectious Disease Outpatient Clinic, Veterans Administration Healthcare Services, Newington
Departments & OrganizationsYale Medical Group
Center for Interdisciplinary Research on AIDS
Internal Medicine: Infectious Diseases: AIDS Care Program
Yale School of Nursing
Sandra Springer, MD is an Associate Professor of Medicine in the Department of Internal Medicine, section of Infectious Diseases at the Yale School of Medicine. She is Board-Certified in Internal Medicine, Infectious Diseases and Addiction Medicine. Dr. Springer has significant research experience with adherence interventions for HIV-infected drug and alcohol dependent persons. She was a recipient of a NIDA-funded K23 mentored career development award, during which she evaluated the use of medication assisted treatment (MAT) to prevent relapse to opioid use as a conduit to care among HIV-infected opioid dependent released prisoners. She developed the first protocol to use buprenorphine as relapse prevention for opioid dependent HIV+ prisoners on day of release and has published these findings that serve as proof of concept that MAT can be effective in maintaining HIV+ released prisoners HIV clinical outcomes. She also has expertise in supervising RCTs by serving as medical director and co-investigator for multiple RCTs including DAART adherence interventions for IDUs and HIV+ released prisoners. She also has considerable clinical and research experience with the use of extended-release naltrexone and has been awarded an R01 from NIAAA as Principal Investigator to evaluate its use to prevent relapse to alcohol use among HIV infected alcohol dependent prisoners transitioning to the community and from NIDA as PI as part of the Seek Test Treat and Retain initiative to evaluate its use to prevent relapse to opioid use among opioid dependent released criminal justice populations as a means to maintain HIV treatment outcomes. She is also a co-investigator on an R01 from NIDA with Dr. Altice evaluating the use of buprenorphine as linkage to HIV testing and conduit to care for opioid dependent persons in Washington D.C and a co-investigator for a NIDA R01 with Dr. Altice (PI) that is implementing extended-release naltrexone for opioid dependent persons in Ukraine. She has a K02 independent scientist award from NIDA as well. Dr. Springer has expertise in the development and implementation of medication-assisted-therapy interventions involving HIV+, drug and alcohol dependent persons involved in the criminal justice setting.